Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seamus Kent

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
JAMA Network Open|March 26, 2025
Quantitative Bias Analysis for Single-Arm Trials With External Control ArmsAlind Gupta, Grace Hsu, Seamus Kent, et al.
Health Technology Assessment (Winchester, England)|November 30, 2020
Outpatient physiotherapy versus home-based rehabilitation for patients at risk of poor outcomes after knee arthroplasty: CORKA RCTKaren L Barker, Jon Room, Ruth Knight, et al.
Pharmacoeconomics|July 27, 2019
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount HoodSeamus Kent, Frauke Becker, Talitha Feenstra, et al.
Journal of Clinical Epidemiology|September 25, 2024
Development of a Canadian Guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision-makingMina Tadrous, Theresa Aves, Christine Fahim, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2025
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trialNoor Wortelboer, Seamus Kent, Inge R Konings, et al.
Journal of the National Cancer Institute|November 21, 2025
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trialNoor Wortelboer, Seamus Kent, Hedwig M Blommestein, et al.
Nature Medicine|January 19, 2023
The impact of the COVID-19 pandemic on cardiovascular disease prevention and managementCaroline E Dale, Rohan Takhar, Raymond Carragher, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Deep phenotyping of 34,128 patients hospitalised with COVID-19 and a comparison with 81,596 influenza patients in America, Europe and Asia: an international network studyEdward Burn, Seng Chan You, Anthony Sena, et al.
The Lancet. Rheumatology|September 1, 2020
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective studyJennifer C E Lane, James Weaver, Kristin Kostka, et al.
Nature Communications|October 7, 2020
Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network studyEdward Burn, Seng Chan You, Anthony G Sena, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
JAMA Network Open|March 26, 2025
Quantitative Bias Analysis for Single-Arm Trials With External Control ArmsAlind Gupta, Grace Hsu, Seamus Kent, et al.
Health Technology Assessment (Winchester, England)|November 30, 2020
Outpatient physiotherapy versus home-based rehabilitation for patients at risk of poor outcomes after knee arthroplasty: CORKA RCTKaren L Barker, Jon Room, Ruth Knight, et al.
Pharmacoeconomics|July 27, 2019
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount HoodSeamus Kent, Frauke Becker, Talitha Feenstra, et al.
Journal of Clinical Epidemiology|September 25, 2024
Development of a Canadian Guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision-makingMina Tadrous, Theresa Aves, Christine Fahim, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2025
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trialNoor Wortelboer, Seamus Kent, Inge R Konings, et al.
Journal of the National Cancer Institute|November 21, 2025
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trialNoor Wortelboer, Seamus Kent, Hedwig M Blommestein, et al.
Nature Medicine|January 19, 2023
The impact of the COVID-19 pandemic on cardiovascular disease prevention and managementCaroline E Dale, Rohan Takhar, Raymond Carragher, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Deep phenotyping of 34,128 patients hospitalised with COVID-19 and a comparison with 81,596 influenza patients in America, Europe and Asia: an international network studyEdward Burn, Seng Chan You, Anthony Sena, et al.
The Lancet. Rheumatology|September 1, 2020
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective studyJennifer C E Lane, James Weaver, Kristin Kostka, et al.
Nature Communications|October 7, 2020
Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network studyEdward Burn, Seng Chan You, Anthony G Sena, et al.
Pageof 4